Phosphatidylserine-targeted liposome for enhanced gliomaselective imaging

Liang Zhang, Amyn A. Habib, Dawen Zhao

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Phosphatidylserine (PS), which is normally intracellular, becomes exposed on the outer surface of viable endothelial cells (ECs) of tumor vasculature. Utilizing a PS-targeting antibody, we have recently established a PS-targeted liposomal (PSL) nanoplatform that has demonstrated to be highly tumor-selective. Because of the vascular lumen-exposed PS that is immediately accessible without a need to penetrate the intact blood brain barrier (BBB), we hypothesize that the systemically administered PS-L binds specifically to tumor vascular ECs, becomes subsequently internalized into the cells and then enables its cargos to be efficiently delivered to glioma parenchyma. To test this, we exploited the dual MRI/optical imaging contrast agents-loaded PS-L and injected it intravenously into mice bearing intracranial U87 glioma. At 24 h, both in vivo optical imaging and MRI depicted enhanced tumor contrast, distinct from the surrounding normal brain. Intriguingly, longitudinal MRI revealed temporal and spatial intratumoral distribution of the PS-L by following MRI contrast changes, which appeared punctate in tumor periphery at an earlier time point (4 h), but became clustering and disseminated throughout the tumor at 24 h post injection. Importantly, glioma-targeting specificity of the PS-L was antigen specific, since a control probe of irrelevant specificity showed minimal accumulation in the glioma. Together, these results indicate that the PS-L nanoplatform enables the enhanced, glioma-targeted delivery of imaging contrast agents by crossing the tumor BBB efficiently, which may also serve as a useful nanoplatform for anti-glioma drugs.

Original languageEnglish (US)
Pages (from-to)38693-38706
Number of pages14
JournalOncotarget
Volume7
Issue number25
DOIs
StatePublished - 2016

Fingerprint

Phosphatidylserines
Liposomes
Glioma
Neoplasms
Optical Imaging
Blood-Brain Barrier
Contrast Media
Endothelial Cells
Blood Vessels
Cluster Analysis
Injections
Antibodies
Brain

Keywords

  • Blood brain barrier (BBB)
  • Glioblastoma multiform
  • Magnetic resonance imaging (MRI)
  • Phosphatidylserine (PS)
  • Tumor vasculature

ASJC Scopus subject areas

  • Oncology

Cite this

Phosphatidylserine-targeted liposome for enhanced gliomaselective imaging. / Zhang, Liang; Habib, Amyn A.; Zhao, Dawen.

In: Oncotarget, Vol. 7, No. 25, 2016, p. 38693-38706.

Research output: Contribution to journalArticle

Zhang, Liang ; Habib, Amyn A. ; Zhao, Dawen. / Phosphatidylserine-targeted liposome for enhanced gliomaselective imaging. In: Oncotarget. 2016 ; Vol. 7, No. 25. pp. 38693-38706.
@article{f515f9fdfafa4de4874b15e38bd27883,
title = "Phosphatidylserine-targeted liposome for enhanced gliomaselective imaging",
abstract = "Phosphatidylserine (PS), which is normally intracellular, becomes exposed on the outer surface of viable endothelial cells (ECs) of tumor vasculature. Utilizing a PS-targeting antibody, we have recently established a PS-targeted liposomal (PSL) nanoplatform that has demonstrated to be highly tumor-selective. Because of the vascular lumen-exposed PS that is immediately accessible without a need to penetrate the intact blood brain barrier (BBB), we hypothesize that the systemically administered PS-L binds specifically to tumor vascular ECs, becomes subsequently internalized into the cells and then enables its cargos to be efficiently delivered to glioma parenchyma. To test this, we exploited the dual MRI/optical imaging contrast agents-loaded PS-L and injected it intravenously into mice bearing intracranial U87 glioma. At 24 h, both in vivo optical imaging and MRI depicted enhanced tumor contrast, distinct from the surrounding normal brain. Intriguingly, longitudinal MRI revealed temporal and spatial intratumoral distribution of the PS-L by following MRI contrast changes, which appeared punctate in tumor periphery at an earlier time point (4 h), but became clustering and disseminated throughout the tumor at 24 h post injection. Importantly, glioma-targeting specificity of the PS-L was antigen specific, since a control probe of irrelevant specificity showed minimal accumulation in the glioma. Together, these results indicate that the PS-L nanoplatform enables the enhanced, glioma-targeted delivery of imaging contrast agents by crossing the tumor BBB efficiently, which may also serve as a useful nanoplatform for anti-glioma drugs.",
keywords = "Blood brain barrier (BBB), Glioblastoma multiform, Magnetic resonance imaging (MRI), Phosphatidylserine (PS), Tumor vasculature",
author = "Liang Zhang and Habib, {Amyn A.} and Dawen Zhao",
year = "2016",
doi = "10.18632/oncotarget.9584",
language = "English (US)",
volume = "7",
pages = "38693--38706",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Phosphatidylserine-targeted liposome for enhanced gliomaselective imaging

AU - Zhang, Liang

AU - Habib, Amyn A.

AU - Zhao, Dawen

PY - 2016

Y1 - 2016

N2 - Phosphatidylserine (PS), which is normally intracellular, becomes exposed on the outer surface of viable endothelial cells (ECs) of tumor vasculature. Utilizing a PS-targeting antibody, we have recently established a PS-targeted liposomal (PSL) nanoplatform that has demonstrated to be highly tumor-selective. Because of the vascular lumen-exposed PS that is immediately accessible without a need to penetrate the intact blood brain barrier (BBB), we hypothesize that the systemically administered PS-L binds specifically to tumor vascular ECs, becomes subsequently internalized into the cells and then enables its cargos to be efficiently delivered to glioma parenchyma. To test this, we exploited the dual MRI/optical imaging contrast agents-loaded PS-L and injected it intravenously into mice bearing intracranial U87 glioma. At 24 h, both in vivo optical imaging and MRI depicted enhanced tumor contrast, distinct from the surrounding normal brain. Intriguingly, longitudinal MRI revealed temporal and spatial intratumoral distribution of the PS-L by following MRI contrast changes, which appeared punctate in tumor periphery at an earlier time point (4 h), but became clustering and disseminated throughout the tumor at 24 h post injection. Importantly, glioma-targeting specificity of the PS-L was antigen specific, since a control probe of irrelevant specificity showed minimal accumulation in the glioma. Together, these results indicate that the PS-L nanoplatform enables the enhanced, glioma-targeted delivery of imaging contrast agents by crossing the tumor BBB efficiently, which may also serve as a useful nanoplatform for anti-glioma drugs.

AB - Phosphatidylserine (PS), which is normally intracellular, becomes exposed on the outer surface of viable endothelial cells (ECs) of tumor vasculature. Utilizing a PS-targeting antibody, we have recently established a PS-targeted liposomal (PSL) nanoplatform that has demonstrated to be highly tumor-selective. Because of the vascular lumen-exposed PS that is immediately accessible without a need to penetrate the intact blood brain barrier (BBB), we hypothesize that the systemically administered PS-L binds specifically to tumor vascular ECs, becomes subsequently internalized into the cells and then enables its cargos to be efficiently delivered to glioma parenchyma. To test this, we exploited the dual MRI/optical imaging contrast agents-loaded PS-L and injected it intravenously into mice bearing intracranial U87 glioma. At 24 h, both in vivo optical imaging and MRI depicted enhanced tumor contrast, distinct from the surrounding normal brain. Intriguingly, longitudinal MRI revealed temporal and spatial intratumoral distribution of the PS-L by following MRI contrast changes, which appeared punctate in tumor periphery at an earlier time point (4 h), but became clustering and disseminated throughout the tumor at 24 h post injection. Importantly, glioma-targeting specificity of the PS-L was antigen specific, since a control probe of irrelevant specificity showed minimal accumulation in the glioma. Together, these results indicate that the PS-L nanoplatform enables the enhanced, glioma-targeted delivery of imaging contrast agents by crossing the tumor BBB efficiently, which may also serve as a useful nanoplatform for anti-glioma drugs.

KW - Blood brain barrier (BBB)

KW - Glioblastoma multiform

KW - Magnetic resonance imaging (MRI)

KW - Phosphatidylserine (PS)

KW - Tumor vasculature

UR - http://www.scopus.com/inward/record.url?scp=84978079720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978079720&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9584

DO - 10.18632/oncotarget.9584

M3 - Article

VL - 7

SP - 38693

EP - 38706

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -